ISRG INTUITIVE SURGICAL INC
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1035267 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.5%
TTM net income YoY7.7%
TTM EPS YoY9.4%
Revenue 3-yr CAGR19.1%
Net income 3-yr CAGR24.9%
Margins
Gross margin67.2%
Operating margin28.4%
Net margin25.5%
FCF margin31.1%
EBITDA margin—
Returns
ROE18.0%
ROA15.3%
ROIC (approx.)19.9%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets16.7%
Debt / equity0.00x
Current ratio3.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.38x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.05B | $2.89B | $2.77B | $2.87B | $2.51B | $2.44B | $2.25B | $2.41B |
| Cost of revenue | $964.40M | $931.90M | $940.30M | $961.90M | $842.70M | $822.10M | $795.70M | $771.30M |
| Gross profit | $2.08B | $1.96B | $1.83B | $1.90B | $1.66B | $1.62B | $1.46B | $1.64B |
| R&D expense | $408.30M | $370.60M | $361.90M | $352.90M | $329.40M | $313.30M | $316.20M | $294.70M |
| SG&A expense | $633.40M | $617.90M | $613.30M | $687.10M | $573.30M | $561.20M | $563.40M | $612.60M |
| Operating income | $592.60M | $971.90M | $855.30M | $864.30M | $759.70M | $743.40M | $578.10M | $734.90M |
| Pretax income | $668.40M | $1.05B | $940.40M | $955.60M | $855.20M | $832.10M | $668.50M | $809.80M |
| Income tax | $144.00M | $231.40M | $114.40M | $156.10M | $146.00M | $167.90M | -$35.20M | $121.80M |
| Net income | $522.80M | $818.10M | $821.50M | $794.80M | $704.40M | $658.40M | $698.40M | $685.70M |
| EPS (basic) | 1.50 | 2.31 | 2.31 | — | 1.98 | 1.84 | 1.95 | — |
| EPS (diluted) | 1.49 | 2.29 | 2.28 | — | 1.95 | 1.81 | 1.92 | — |
| Weighted avg. shares (diluted) | 351.60M | 357.30M | 359.80M | — | 361.80M | 364.10M | 364.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.98B | $2.76B | $2.01B | $3.37B | $2.85B | $3.45B | $2.62B | $2.06B |
| Short-term investments | $1.06B | $2.46B | $2.51B | $2.57B | $2.10B | $1.92B | $1.94B | $1.99B |
| Receivables | $1.72B | $1.67B | $1.60B | $1.53B | $1.26B | $1.27B | $1.22B | $1.23B |
| Inventory | $2.13B | $2.03B | $1.95B | $1.84B | $1.78B | $1.67B | $1.55B | $1.49B |
| Current assets | $8.43B | $9.54B | $8.81B | $9.78B | $8.53B | $8.75B | $7.66B | $7.11B |
| PP&E, net | $5.68B | $5.55B | $5.45B | $5.34B | $5.15B | $4.99B | $4.80B | $4.65B |
| Goodwill | $557.80M | $580.60M | $613.20M | $370.30M | $348.10M | $348.70M | $347.50M | $347.50M |
| Intangibles | $196.70M | $198.00M | $173.50M | $17.10M | $14.50M | $17.90M | $19.60M | $23.00M |
| Total assets | $19.35B | $20.88B | $20.11B | $20.46B | $19.35B | $20.16B | $19.22B | $18.74B |
| Current liabilities | $2.53B | $1.92B | $1.91B | $2.01B | $1.80B | $1.69B | $1.54B | $1.75B |
| Total liabilities | $3.23B | $2.58B | $2.51B | $2.52B | $2.31B | $2.21B | $2.01B | $2.21B |
| Shareholders' equity | $15.99B | $18.17B | $17.47B | $17.82B | $16.93B | $17.85B | $17.11B | $16.43B |
| Shares outstanding | 346.60M | 353.90M | 354.40M | 355.10M | 354.90M | 358.40M | 358.40M | 356.60M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.22B | $1.06B | $911.90M | $892.50M | $841.00M | $715.40M | $581.60M | $822.60M |
| Capital expenditure | $113.10M | $112.60M | $103.30M | $162.50M | $105.40M | $155.30M | $116.60M | $312.00M |
| Free cash flow | $1.11B | $948.40M | $808.60M | $730.00M | $735.60M | $560.10M | $465.00M | $510.60M |
| Investing cash flow | $1.90B | -$26.60M | -$914.50M | -$209.40M | $401.00M | $260.70M | $213.50M | -$1.26B |
| Financing cash flow | -$2.89B | -$287.90M | -$1.35B | -$137.50M | -$1.84B | -$147.80M | -$235.80M | $49.40M |
| Stock-based compensation | $215.70M | $212.80M | $209.50M | $203.30M | $206.00M | $199.90M | $185.20M | $177.00M |
| Dividends paid | — | — | — | — | $0 | — | — | — |
| Share buybacks | $2.98B | $320.30M | $1.12B | $201.00M | $1.91B | $181.00M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.